Last edition
News about "Roche"
Roche to Acquire 89bio in Deal Worth Up to USD 3.5 Billion
Roche has entered into a merger agreement to acquire 89bio, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases.
Roche | 18/09/2025 | By Dineshwori
Pfizer, Novartis, Roche Lead Net-Zero Pharma Supply Chain Transition
Europe currently dominates the global net-zero pharma supply chain market supported by strict climate regulations, while Asia-Pacific is the fastest-growing region, spurred by new government-led sustainability policies.
Roche | 11/09/2025 | By Dineshwori
Roche Deploys Contivue Manufacturing Platform with CE Mark for nAMD Continuous Drug Delivery
Roche has received CE marking in the European Union for Contivue, its innovative Port Delivery Platform for administering Susvimo in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
Roche | 04/09/2025 | By Darshana
Foresight Diagnostics, a privately held cancer diagnostics company, has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems, resolving ongoing litigation between the parties. As part of the resolution, all claims against Foresight, its founders, and Stanford University have been dismissed with prejudice.
Roche | 01/09/2025 | By Darshana
Atezolizumab will be provided by Genentech for use in Pilatus’ clinical research; PLT012 is Pilatus’ immunomodulatory candidate.
Roche | 18/08/2025 | By Abha
The global biologics and biosimilars market is expected to reach approximately USD 600 billion by 2032, expanding at a compound annual growth rate (CAGR) of around 6.33 percent during the forecast period.
Roche | 15/07/2025 | By Dineshwori
Oxford BioTherapeutics and Roche to Research on Novel Targets for Antibody-Based Therapeutics
OBT’s recently launched enhanced proprietary OGAP®-Verify discovery platform enables greater sensitivity and thereby the selection of targets with improved attributes for drug development.
Roche | 25/03/2025 | By Aishwarya | 135
Zealand Pharma and Roche to Develop and Commercialize Petrelintide
The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.
Roche | 15/03/2025 | By Aishwarya | 181
Innovent Signs Exclusive Global License Deal with Roche for Novel DLL3 Antibody Drug Conjugate
IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors.
Roche | 02/01/2025 | By Aishwarya | 195
Roche Announces Acquisition of Poseida Therapeutics
The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.
Roche | 03/12/2024 | By Aishwarya | 161
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy